These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39417110)

  • 21. Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.
    Ge L; Luo Y; Li X; Hu Y; Sun L; Bu F; Shan D; Liu J
    EClinicalMedicine; 2024 Nov; 77():102859. PubMed ID: 39430612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
    AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13.
    Hunt GM; Ledwaba J; Salimo A; Kalimashe M; Dinh TH; Jackson D; Sherman G; Puren A; Ngandu NK; Lombard C; Morris L; Goga A
    BMC Infect Dis; 2019 Sep; 19(Suppl 1):787. PubMed ID: 31526373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV drug resistance tendencies in Latvia.
    Kolupajeva T; Aldins P; Guseva L; Dusacka D; Sondore V; Viksna L; Rozentale B
    Cent Eur J Public Health; 2008 Sep; 16(3):138-40. PubMed ID: 18935781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
    Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW
    PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E
    PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.
    Lippman SA; Mooney AC; Puren A; Hunt G; Grignon JS; Prach LM; Gilmore HJ; Truong HM; Barnhart S; Liegler T
    BMC Infect Dis; 2020 Mar; 20(1):248. PubMed ID: 32216752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda.
    Ndikabona G; Alege JB; Kirirabwa NS; Kimuli D
    BMC Public Health; 2021 Dec; 21(1):2294. PubMed ID: 34922502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
    Ross LL; Shortino D; Shaefer MS
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):672-679. PubMed ID: 29732898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
    Reynolds SJ; Laeyendecker O; Nakigozi G; Gallant JE; Huang W; Hudelson SE; Quinn TC; Newell K; Serwadda D; Gray RH; Wawer MJ; Eshleman SH
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1739-44. PubMed ID: 22443282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High level of pre-treatment and acquired HIV drug resistance in Honduras: a nationally representative survey, 2016-17.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Meza RI; Sierra T; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Paredes M; Rodríguez A; Juárez SI; Farach N; Videa G; Lara B; Rodríguez E; Ardón E; Sajquim E; Lorenzana R; Ravasi G; Northbrook S; Reyes-Terán G; Ávila-Ríos S
    J Antimicrob Chemother; 2020 Jul; 75(7):1932-1942. PubMed ID: 32303063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011.
    Bontell I; Häggblom A; Bratt G; Albert J; Sönnerborg A
    PLoS One; 2013; 8(3):e59337. PubMed ID: 23533618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA).
    Reniers G; Slaymaker E; Nakiyingi-Miiro J; Nyamukapa C; Crampin AC; Herbst K; Urassa M; Otieno F; Gregson S; Sewe M; Michael D; Lutalo T; Hosegood V; Kasamba I; Price A; Nabukalu D; Mclean E; Zaba B;
    AIDS; 2014 Nov; 28 Suppl 4(4):S533-42. PubMed ID: 25406756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.
    Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates.
    Rhee SY; Kassaye SG; Barrow G; Sundaramurthi JC; Jordan MR; Shafer RW
    J Int AIDS Soc; 2020 Sep; 23(9):e25611. PubMed ID: 32936523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
    Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.